Ipswich Investment Management Co. Inc. acquired a new position in Agilent Technologies Inc (NYSE:A) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 981 shares of the medical research company’s stock, valued at approximately $66,000.

Other institutional investors have also added to or reduced their stakes in the company. CENTRAL TRUST Co boosted its holdings in Agilent Technologies by 175.1% in the fourth quarter. CENTRAL TRUST Co now owns 1,139 shares of the medical research company’s stock worth $77,000 after purchasing an additional 725 shares during the period. TRUE Private Wealth Advisors acquired a new position in Agilent Technologies in the third quarter worth $181,000. AMG National Trust Bank acquired a new position in Agilent Technologies in the third quarter worth $212,000. UMB Bank N A MO acquired a new position in shares of Agilent Technologies during the third quarter valued at $219,000. Finally, Lido Advisors LLC acquired a new position in shares of Agilent Technologies during the third quarter valued at $220,000.

Shares of A opened at $70.82 on Friday. Agilent Technologies Inc has a 1 year low of $60.42 and a 1 year high of $75.11. The firm has a market cap of $22.31 billion, a PE ratio of 25.38, a PEG ratio of 1.96 and a beta of 1.26. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.29 and a quick ratio of 2.74.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 19th. The medical research company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.07. Agilent Technologies had a net margin of 6.43% and a return on equity of 19.84%. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter in the previous year, the company posted $0.67 earnings per share. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, analysts anticipate that Agilent Technologies Inc will post 3.04 earnings per share for the current year.

Agilent Technologies announced that its Board of Directors has authorized a share repurchase plan on Monday, November 19th that authorizes the company to buyback $1.75 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 8.8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 23rd. Investors of record on Monday, December 31st will be paid a dividend of $0.164 per share. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.15. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.93%. The ex-dividend date is Friday, December 28th. Agilent Technologies’s payout ratio is currently 23.66%.

In related news, VP Rodney Gonsalves sold 1,500 shares of Agilent Technologies stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $71.06, for a total transaction of $106,590.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael R. Mcmullen sold 15,923 shares of Agilent Technologies stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $73.20, for a total transaction of $1,165,563.60. Following the sale, the chief executive officer now owns 492,546 shares in the company, valued at $36,054,367.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,325 shares of company stock worth $1,930,902.

Several equities analysts have recently issued reports on the stock. ValuEngine downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. Zacks Investment Research downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th. Morgan Stanley boosted their price target on shares of Agilent Technologies from $86.00 to $89.00 and gave the company an “overweight” rating in a report on Tuesday, November 20th. Cleveland Research downgraded shares of Agilent Technologies from a “buy” rating to a “neutral” rating in a report on Monday, November 12th. Finally, Needham & Company LLC assumed coverage on shares of Agilent Technologies in a report on Wednesday, January 2nd. They set a “buy” rating and a $77.00 price target for the company. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $79.71.

TRADEMARK VIOLATION NOTICE: “Ipswich Investment Management Co. Inc. Acquires Shares of 981 Agilent Technologies Inc (A)” was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/ipswich-investment-management-co-inc-acquires-shares-of-981-agilent-technologies-inc-a/2754533.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

See Also: Why do corrections happen?

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.